Amyotrophic lateral sclerosis: New perpectives and update

Neurology International

Volumn 7, Issue 2, 2015, Pages 39-47

  Orsini, Marco ^a,b   Oliveira, Acary Bulle ^c   Nascimento, Osvaldo J M ^a   Reis, Carlos Henrique Melo ^a   Leite, Marco Antonio Araujo ^a   de Souza, Jano Alves ^a   Pupe, Camila ^a   de Souza, Olivia Gameiro ^a   Bastos, Victor Hugo ^d   de Freitas, Marcos R G ^a   Teixeira, Silmar ^d   Bruno, Carlos ^a   Davidovich, Eduardo ^a   Smidt, Benny ^c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b UNISUAM   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

Amyotrophic lateral sclerosis; Diagnosis; Neurodegenerative diseases; Rehabilitation; Treatment

Indexed keywords

RILUZOLE; SYNAPTOBREVIN;

AMYOTROPHIC LATERAL SCLEROSIS; BREATHING MUSCLE; BULBAR PARALYSIS; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; KENNEDY DISEASE; MOTONEURON; PATHOGENICITY; PHYSICAL DISABILITY; PREVALENCE; PRIMARY LATERAL SCLEROSIS; REVIEW; TIDAL VOLUME; UNITED STATES; VITAL CAPACITY;

EID: 84942567327     PISSN: 20358385     EISSN: 20358377     Source Type: Journal    
DOI: 10.4081/ni.2015.5885     Document Type: Review

References (68)

1. Rowland LP, ed. Diverse forms of motor neuron diseases. In: Human motor neuron diseases. New York: Raven Press; 1982.
2. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007;6:913-25.
3. Goodall EF, Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 2006;8:1-22.
4. Ciesler J, Sari Y. Neurotrophic peptides: potential drugs for treatment of amyotrophic lateral sclerosis and Alzheimer's disease. Open J Neurosci 2013;3:1-13.
5. Oliveira AS, Pereira RD. Amyotrophic lateral sclerosis: three letters that change the people's life. For ever. Arq Neuropsiquiatr 2009;67: 50-82.
6. Hirano M. Motor neuron diseases. In: Brust JCM, ed. Current: diagnosis and treatment. Philadaelphia: McGraw-Hill 2011; p 574.
7. Orsini M, De Freitas MRG, Nascimento OJM, et al. Clinical and functional profile of amyotrophic lateral sclerosis patients: a one year follow up. Am J Neurosci 2011;2:28-34.
8. De Freitas MRG. Esclerose lateral amiotró-ficalDoenca de Charcot. In: Melo-Souza S, ED. Tratamento das Doencas Neurológicas. Vila Mariana; Guanabara Koogan;2013.p 1324.
9. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev 2006;7:710-23.
10. Orsini M, De Freitas MRG, Oliveira ASB, et al. Esclerosis lateral amiotrófica esporádica de inicio juvenil. Rev Neurol 2010;50:442-4.
11. Wicklund MP. Amyotrophic lateral sclerosis: possible role of environmental influences. Neurol Clin 2005;23:461-84.
12. Maarten D, Ludo VDB, Robberecht W. Microglia in amyotrophic lateral sclerosis. Acta Neurol Belg 2007;107:63-70.
13. Shaw CE, Al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001;1:69-76.
14. Oey PL, Vos PE, Wieneke GH, ET AL. Subtle involvement of the sympathetic nervous system in amyotrophic lateral sclerosis. Muscle Nerve 2002;25:402-8.
15. Williams C, Kozlowski MA, Hinton DR, Miller CA. Degeneration of spinocerebellar neurons in amyotrophic lateral sclerosis. Ann Neurol 1990;27:215-25.
16. Lloyd CM, Richardson MP, Brooks DJ, et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand (11) C.flumazenil. Brain 2000;123:2289-96.
17. Nascimento OJM, Orsini M, Pupe C, et al. Amyotrophic lateral sclerosis with sensitive findings: A multisystem disorder? Rev Neurocienc 2010;18:320-3.
18. Nass RD, Meister IG, Haupt WF, Fink GR. ALS and frontotemporal dementia - case report and review of the literature. Fortschr Neurol Psychiatr 2012;80:711-9. 2007;6:913-25.
19. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994-1003.
20. Cappellari A, Ciammola A, Silani V. The pseudopolyneuritic form of amyotrophic lateral sclerosis (Patrikios' disease). Electromyogr Clin Neurophysiol 2008;48:75-81.
21. Presto B, Orsini M, Presto LDN, et al. Noninvasive ventilation and respiratory physical therapy for amyotrophic lateral sclerosis patients. Rev Neurocien 2009;17:293-7.
22. Paschoal IA, Villalba WO, Pereira MC. Chronic respiratory failure in patients with neuromuscular diseases: diagnosis and treatment. J Bras Pneumol 2007;33:81-92
23. Lévêque N. Speech therapy guidelines in patients with amyotrophic lateral sclerosis. Rev Neurol (Paris) 2006;162:269-72.
24. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
25. Chiö A. 1S1S survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999;246:1111-5.
26. Fonseca LA, Fontes SV, Anequini 1P. Emergency guidelines for professionals who treat patients with Amyotrophic Lateral Sclerosis. Rev Neurocienc 2012;20:260-5.
27. The ALS society of Canada. Manual for People Living with ALS homepage on the 1nternet.Toronto-Ontario. Available from: http://www.als.ca/als_manuals.aspx.
28. Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60:1252-8.
29. López-Pisón J, Rebage V, Baldellou-Vázquez A, et al. Enfermedades neuromus-culares hereditárias en pediatría. Nuestra experiencia de 14 años. Rev Neurol 2005;41:145-50.
30. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000;15:228-37.
31. Araújo APQC, Ramos VG, Cabello PH. Dificuldades diagnósticas na atrofia mus-cula espinhal. Arq Neuropsiquiatr 2005;63:145-9.
32. Le Forestier N, Maisonobe T, Spelle L, et al. Primary lateral sclerosis: further clarification. J Neurol Sci 2001;185:95-100.
33. Andersen PM, Nilsson P, Keranen ML, et al. Phenotypic heterogeneity in motor neuron diseases patients with Cu/Zn-superox-ido desmutase in Scandinavian. Brain 1997;120:1723-37.
34. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-700.
35. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El escorial and Arlie house diagnostic criteria: apopulation base study. Arch Neurol 2000;57:1171-6.
36. Nodera H, Izumi Y, Kaji R. New diagnostic criteria of ALS (Awaji criteria). Brain Nerve 2007;59:1023-9.
37. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639-49.
38. Schrooten M, Smetcoren C, Robberecht W, Van Damme, P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol 2011;70:79-83.
39. Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009;10:53-7.
40. Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000;23:1488-502.
41. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310-23.
42. Chieia MAT. Esclerose lateral amiotrófica: considerares a respeito dos criterios diagnósticos. Thesis dissertation., Universidade Federal de Sao Paulo/Escola Paulista de Medicina, 2008.
43. Donaghy M. Classification and clinical features of motor neuron diseases and motor neuropathies in adults. J Neurol 1999;246:331-3.
44. Orsini M, De Freitas MRG, Silva JG, et al. Motor neuron disease and acquired axonal neuropathy association in HIV infection: case report and update. Curr HIV Res 2012;10:1-6.
45. Silani V, Borasio D. Honesty and hope: announcement of diagnosis in ALS. Neurology 1999;53:S37-9.
46. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclero-sis(ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;CD001447.
47. Bach JR. Amyotrophic lateral sclerosis. Prolongation of life by noninvasive respiratory aids. Chest 2002;122:92-8.
48. Metha S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540-77.
49. Ertekin C, Aydogdu I. Neurophysiology of swallowing. Clin Neurophysiol 2003;114:2226-44.
50. Stanich P, Pereira AML, Chiappetta ALM, et al. Suplementacäo nutricional em pacientes com doenca do neurónio motor/esclerose lateral amiotrófica. Rev Bras Nutr Clin 2004;19:70-8.
51. Karsarskis EJ, Berryman S, Vanderleest JG, et al. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximith of death. Am J Clin Nutr 1996;63:130-7.
52. Hartmann S, Van Der Weg B, Binek J, et al. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis: role of BiPAP ventilation. ALS 2007;8:79.
53. Kent RD, Vorperian HK, Kent JF, Duffy JR. Voice dysfunction in dysarthria: application of the Multi-Dimensional Voice Program. J Commun Disord 2003;36:281-306.
54. Van den Berg LH, van den Berg JP, Mathus-Vliegen EM, et al. [The symptomatic treatment of amyotrophic lateral sclerosis]. Ned Tijdschr Geneeskd 2004;148:513-8. [Article in Dutch].
55. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of rilu-zole in ALS. Neurology 1996;47:S242-250.
56. Brooks BR, Sanjak M. Disease-modifying drug therapies. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:68-75.
57. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1999;52:1311-23.
58. Áberg UW, Saarinen N, Abrahamsson A, et al. Tamoxifen and flaxseed alter angiogen-esis regulators in normal human breast tissue in vivo. PLoS One 2011;6:1-11.
59. Traynor BJ, Bruijn I, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology 2006;67:20-7.
60. Briscoe J, Pierani A, Jessell TM, et al. A homeodomain protein code specifies progenitor cell identify and neuronal fate in the ventral neural tube. Cell 2000;101:435-45.
61. Yan J, Xu L, Welsh AM, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006;24:1976-85.
62. Corti S, Locatelli F, Papadinitrion D, et al. Neural stem cells Lewis X+CXCR4+ modify disease progression in an ALS model. Brain 2007;130:1289-305.
63. DiGiorgio FP, Boulting GL, Bobrowicz S, et al. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-caus- ing mutations. Cell Stem Cell 2008;3:637-48.
64. Mazzini J, Mareshi K, Ferrerò I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265:78-83.
65. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiat- ed into motor neuron. Science 2008;321:1218-21.
66. Yan J, Xu L, Welsh AM, et al. Extensive neuronal differentiation of human neural stem cells grafts in adult rat spinal cord. PLoS Med 2007;4:318-32.
67. Feldman EV, Boulis NM, Hur J, et al. Transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014;75:363-73.
68. Riley J, Federic T, Park J, et al. Cervical spinal cord therapeutics delivery: preclini-cal safety validation of a stabilized microinjection platform. Neurosusrgery 2009;65:754-61.